| Literature DB >> 28251157 |
Tijana J Dimkić Tomić1, Andrej M Savić2, Aleksandra S Vidaković1, Sindi Z Rodić1, Milica S Isaković2, Cristina Rodríguez-de-Pablo3, Thierry Keller3, Ljubica M Konstantinović1.
Abstract
The ArmAssist is a simple low-cost robotic system for upper limb motor training that combines known benefits of repetitive task-oriented training, greater intensity of practice, and less dependence on therapist assistance. The aim of this preliminary study was to compare the efficacy of ArmAssist (AA) robotic training against matched conventional arm training in subacute stroke subjects with moderate-to-severe upper limb impairment. Twenty-six subjects were enrolled within 3 months of stroke and randomly assigned to the AA group or Control group (n = 13 each). Both groups were trained 5 days per week for 3 weeks. The primary outcome measure was Fugl-Meyer Assessment-Upper Extremity (FMA-UE) motor score, and the secondary outcomes were Wolf Motor Function Test-Functional Ability Scale (WMFT-FAS) and Barthel index (BI). The AA group, in comparison to the Control group, showed significantly greater increases in FMA-UE score (18.0 ± 9.4 versus 7.5 ± 5.5, p = 0.002) and WMFT-FAS score (14.1 ± 7.9 versus 6.7 ± 7.8, p = 0.025) after 3 weeks of treatment, whereas the increase in BI was not significant (21.2 ± 24.8 versus 13.1 ± 10.7, p = 0.292). There were no adverse events. We conclude that arm training using the AA robotic device is safe and able to reduce motor deficits more effectively than matched conventional arm training in subacute phase of stroke. The study has been registered at the ClinicalTrials.gov, ID: NCT02729649.Entities:
Mesh:
Year: 2017 PMID: 28251157 PMCID: PMC5306984 DOI: 10.1155/2017/7659893
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1ArmAssist training.
Figure 2Conventional arm training.
Figure 3Study flow diagram.
Demographic data and baseline clinical characteristics.
| AA group | Control group |
| |
|---|---|---|---|
| Age (years)1 | 56.5 ± 7.4 | 58.3 ± 5.2 | 0.471 |
| Sex2 | 0.322 | ||
| Male | 12 (92.3%) | 9 (69.2%) | |
| Female | 1 (7.7%) | 4 (30.8%) | |
| Duration (days)1 | 35.3 ± 9.7 | 37.3 ± 7.7 | 0.566 |
| Affected side2 | 0.810 | ||
| Left | 5 (38.5%) | 6 (46.2%) | |
| Right | 8 (61.5%) | 7 (53.8%) | |
| Type of stroke2 | 0.617 | ||
| Ischemic | 12 (92.3%) | 11 (84.6%) | |
| Hemorrhagic | 1 (7.7%) | 2 (15.4%) | |
| NIHSS1 | 6.1 ± 1.6 | 6.2 ± 2.2 | 0.839 |
NIHSS: National Institute of Health Stroke Scale. 1Mean ± standard deviation. 2Frequency (percentage). Statistically significant (p < 0.05).
Baseline outcome measures.
| AA group | Control group |
| |
|---|---|---|---|
| FMA-UE1 | 26.5 ± 7.7 | 26.6 ± 7.5 | 0.980 |
| FMA-UE1 shoulder/elbow | 18.5 ± 6.0 | 18.7 ± 5.2 | 0.945 |
| WMFT-FAS1 | 44.2 ± 12.2 | 42.4 ± 13.3 | 0.727 |
| WMFT-FAS1 shoulder/elbow | 24.5 ± 5.5 | 22.8 ± 4.9 | 0.419 |
| BI1 | 65.0 ± 26.1 | 65.4 ± 19.8 | 0.967 |
FMA-UE: Fugl-Meyer Assessment of Upper Extremity, WMFT-FAS: Wolf Motor Function Test-Function Ability Scale, BI: Barthel index. 1Mean ± standard deviation. Statistically significant (p < 0.05).
Changes in outcome measures from the period before to the period after the treatment.
| Outcome measure | AA group | Control group |
|
|
|---|---|---|---|---|
| FMA-UE1 | 18.0 ± 9.4 | 7.5 ± 5.5 |
|
|
| FMA-UE1 shoulder/elbow | 9.1 ± 6.3 | 3.4 ± 2.6 |
|
|
| WMFT-FAS1 | 14.1 ± 7.9 | 6.7 ± 7.8 |
|
|
| WMFT-FAS1 shoulder/elbow | 6.7 ± 7.8 | 3.2 ± 2.7 |
|
|
| BI1 | 21.2 ± 24.8 | 13.1 ± 10.7 | 0.292 | — |
FMA-UE: Fugl-Meyer Assessment of Upper Extremity. WMFT: Wolf Motor Function Test. BI: Barthel Index. Effect size Cohen's d (<0.2 small; 0.2–0.8 medium; and >0.8 large). 1Mean ± standard deviation. Statistically significant (p < 0.05).